Quinolone antibacterials currently are second-line treatment for tuberculosis and are used extensively when patients become resistant to or are intolerant of first-line treatment. Unfortunately, quinolone resistance is becoming prevalent. We are working with M. tuberculosis, gyrase, the target of quinolone antibacterials to define mechanisms that can be used to overcome drug resistance.
| Neil Osheroff [Email] Department of Biochemistry |
|
| Location |
Nashville with the eventual possibility of Tres Cantos, Spain |
| Contacts | N/A |
| Program Type |
Research |
| Funding Type |
Scholarships, Fellowships, Internships, Grants |
| Region |
Africa, Asia |
| Global Health Topics |
Basic Sciences, Infectious Diseases |
| Eligibility |
Graduate students (non-clinical); Medical students (MD); Post-doctoral students, residents, or trainees |
| Program Length |
Flexible, depending on the individuals interests and needs |
| VU Affiliation |
The program is affiliated with Vanderbilt. |
| Language(s) |
The program does not have a language requirement. |